Combined therapy of the MERTK/Flt3 inhibitor UNC2025 and HDAC inhibitor Trichostatin-A decreases spheroid viability and proliferation and reverses mesenchymal transition in meningioma spheroids. Here, FLT3 is linked to meningioma.